168 related articles for article (PubMed ID: 9571393)
1. Capromab pendetide. A review of its use as an imaging agent in prostate cancer.
Lamb HM; Faulds D
Drugs Aging; 1998 Apr; 12(4):293-304. PubMed ID: 9571393
[TBL] [Abstract][Full Text] [Related]
2. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Rosenthal SA; Haseman MK; Polascik TJ
Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
4. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
5. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
Manyak MJ; Hinkle GH; Olsen JO; Chiaccherini RP; Partin AW; Piantadosi S; Burgers JK; Texter JH; Neal CE; Libertino JA; Wright GL; Maguire RT
Urology; 1999 Dec; 54(6):1058-63. PubMed ID: 10604708
[TBL] [Abstract][Full Text] [Related]
6. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.
Hardie AD; Rieter WJ; Bradshaw ML; Gordon LL; Young MA; Keane TE
World J Urol; 2013 Dec; 31(6):1327-32. PubMed ID: 23595605
[TBL] [Abstract][Full Text] [Related]
7. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
9. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.
Petronis JD; Regan F; Lin K
Clin Nucl Med; 1998 Oct; 23(10):672-7. PubMed ID: 9790041
[TBL] [Abstract][Full Text] [Related]
10. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
[TBL] [Abstract][Full Text] [Related]
11. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide.
Hinkle GH; Burgers JK; Neal CE; Texter JH; Kahn D; Williams RD; Maguire R; Rogers B; Olsen JO; Badalament RA
Cancer; 1998 Aug; 83(4):739-47. PubMed ID: 9708939
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
[TBL] [Abstract][Full Text] [Related]
13. 111In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its 111In-labelled murine antibody in the evaluation of prostate cancer.
Plut EM; Hinkle GH
BioDrugs; 2000 Jun; 13(6):437-47. PubMed ID: 18034550
[TBL] [Abstract][Full Text] [Related]
14. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer.
Sodee DB; Conant R; Chalfant M; Miron S; Klein E; Bahnson R; Spirnak JP; Carlin B; Bellon EM; Rogers B
Clin Nucl Med; 1996 Oct; 21(10):759-67. PubMed ID: 8896922
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunoguided surgery using indium-111 capromab pendetide (PROSTASCINT) to diagnose supraclavicular metastasis from prostate cancer.
Anderson RS; Eifert B; Tartt S; King P
Urology; 2000 Oct; 56(4):669. PubMed ID: 11018634
[TBL] [Abstract][Full Text] [Related]
17. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.
Wong WW; Schild SE; Vora SA; Ezzell GA; Nguyen BD; Ram PC; Roarke MC
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e423-9. PubMed ID: 21477947
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
[TBL] [Abstract][Full Text] [Related]
19. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.
Thomas CT; Bradshaw PT; Pollock BH; Montie JE; Taylor JM; Thames HD; McLaughlin PW; DeBiose DA; Hussey DH; Wahl RL
J Clin Oncol; 2003 May; 21(9):1715-21. PubMed ID: 12721246
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
